Voyager Therapeutics, Inc. is a biotechnology company focused on developing genetic medicines to treat neurological diseases. Its pipeline includes therapies for conditions such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease. The company utilizes its TRACER™ AAV capsid discovery platform to create novel capsids that enhance the delivery of treatments across the blood-brain barrier. Voyager operates primarily in the field of gene therapy, targeting central nervous system disorders.
